UNSPSC 51433502: Amiquinsin

This classification denotes an antihypertensive agent with the molecular formula C11H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85HK85C137, chemically known as 4-amino-6,7-dimethoxyquinoline but generally known as amiquinsin, which bears US NIH Compound Identifier 23510. Amiquinsin most often comes in base and hydrochloride forms. European Medicines Agency schedules Amiquinsin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05456MIG.

UNSPSC 51433502 Amiquinsin is a Commodity code under which state and local governments procure advanced life support and emergency medications, generic pharmaceuticals, and over-the-counter products for use by fire rescue services, state health agencies, and public health systems. The scope of work includes sealed competitive bidding for specific medication line items with strict expiration and shelf-life requirements, cooperative purchasing arrangements for multi-source generic drugs distributed through authorized wholesale channels, and strategic sourcing initiatives to establish direct manufacturer relationships and optimize pharmacy benefit management for state employee and Medicaid populations. Issuing bodies span city purchasing departments, state health and human services commissions, and multistate cooperative purchasing alliances; the City of Tampa and the Texas Health and Human Services Commission appear as recent active buyers, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers contracts benefiting multiple state and local jurisdictions across Oregon and Minnesota.

Activity under the code concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB No. 26P00188 for Advanced Life Support Medications on April 24, 2026, with a due date of April 8, 2026, soliciting sealed bids for epinephrine, labetalol, adenosine, and diltiazem vials for Tampa Fire Rescue with an estimated contract value of $40,000.00 and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount capped at $10,000. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with proposals due March 26, 2026, requiring vendors to supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription fulfillment and cost management strategies for a Therapeutic Pharmacy Initiative; this was an information-gathering phase with no formal award values or timelines, designed to inform subsequent formal solicitation development.